Multiplexed Gene Expression and Pharmacogenetics Analysis: Laboratory Testing in an Era of Personalized Medicine
We are quickly moving towards the era of patient-tailored therapies and predictive medicine. Clinical treatments in this age will require a fundamental understanding of the molecular heterogeneity of tumors, including the delineation of individualized genetic profiles of cancer cells. Progress towards predictive medicine will entail understanding genetic variation between individual patients, particularly with regard to genes encoding drug metabolizing enzymes involved in activation or inactivation of chemotherapeutic agents. These are the main goals of our research- to characterize tumors by their molecular genetic profiles and identify biomarker signatures that characterize distinct subsets of the (apparently) same disease. Our work aims to identify new biomarkers and to then develop laboratory assays that can be used in the clinical management of cancer patients. In addition, we seek to develop assays for genotyping individuals to determine their ability (or inability) to effectively metabolize cancer drugs. Design and application of both biomarker-based and genotyping-based assays will serve to maximize therapeutic efficacy and reduce adverse reactions to chemotherapeutic agents.
Director, Special Chemistry Laboratory
New York Presbyterian Hospital- Columbia University Medical Center
1. Huang X., Spink D.C., Schneider E., Ling H., Rai A.J.
, Rosano T.G., Chen B., Cao Z.T.
Measurement of Unconjugated Estriol in Serum by Liquid Chromatography/Tandem
Mass Spectrometry and Assessment of the Accuracy of Chemiluminescent Immunoassays.Clinical Chemistry
(2013), 2013 Nov 19. [Epub ahead of print].
2. Hollevoet K., Reitsma J.B., Creaney J., Grigoriu B.D., Robinson B.W., Scherpereel A., Cristaudo A., Pass H.I., Nackaerts K., Rodríguez Portal J.A., Schneider J., Muley T., Di Serio F., Baas P., Tomasetti M., Rai A.J.
, van Meerbeeck J.P.
Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis.J Clinical Oncology
3. Kharbanda, A, Rai A.J.
, Cosme, Y., Liu, K.,Dayan, P.
Novel Serum and Urine Markers for Pediatric Appendicitis. Academic Emergency Medicine
(2012); 19(1):56-62. Epub 2012 Jan 5.
4. Rai A.J.
, Yee, J., and Fleisher, M.
Biomarkers in the era of personalized medicine - a multiplexed SNP assay using capillary electrophoresis for assessing drug metabolism capacity. Scand J Clin Lab Invest
(2010); Suppl. 242:15-18.
5. Rai A.J.
, Flores, R.M., Mathew, A., Gonzalez-Espinoza, R., Bott, M., Ladanyi, M., Rusch, V., and Fleisher, M. Mesothelin and Osteopontin: Analytical Validation, Reference Range Determination, and Levels in Mesothelioma Patients.
In press, Clinical Chemistry Laboratory Medicine
6. Rai A.J.
, Yu, C.T., Udar, N., Fleisher, M. Multiplexed SNP Analysis: Design of a Custom Panel for 2C9 Warfarin Dosing.Clinical Chemistry
55(4):823-6. Epub (2009) Feb 20
7. Rai A.J.
, Kamath R., Gerald W., Fleisher M. Analytical Validation of the GeXP analyzer and Design of a Workflow for Cancer Biomarker Discovery using Multiplexed Gene Expression Profiling. Analytical and Bioanalytical Chemistry
393(5):1505-11. Epub (2008) Oct 29
8. The Urinary Proteome, Alex J. Rai
(Editor), published by Humana Press (Springer, 2010)
Honors and Awards
AACC Award for Outstanding Scientific Achievements by a Young Investigator 2008
American Association for Clinical Chemistry (AACC)2004
Young Investigator Award- Human Proteome Organization
Human Proteome Organization (HUPO) World Congress
Beijing, China (October 23-27, 2004)2002
Paul E. Strandjord Young Investigator Award
Academy of Clinical Laboratory Physicians and Scientists (ACLPS)
Committees , Council, and Professional Society Memberships
CAP Molecular Oncology Committee, AACC-Liaison (2013-present)
AACC Molecular Pathology Division, Chair (2012-2013)
AACC Proteomics Division, Executive Board (2010-present)
AACC, New Jersey Local Section, Chair (2014-2015)